TG and colorectal cancer: In particular, the study by Schirripa et al. [15], demonstrated how the efficacy of regorafenib could be related to the baseline value of thyroid hormones in patients with colorectal cancer; patients were grouped according to baseline fT3/fT4 ratio tertiles of values in low, intermediate and high.